在南印度人口中的1型糖尿病中维生素D受体基因多态性
Karthick Rajendran1, Pushpa Saravanan2, Vasuki Ranganathan2
1Multidisciplinary Research Unit (MRU), Madras Medical College, Chennai, Tamil Nadu, India.
International journal of immunogenetics
|March 2, 2026
概括
在1型糖尿病 (T1D) 患者中,维生素D水平较低. 维生素D受体 (VDR) 基因中的BsmI多态性和特定的单质类型与南印度人T1D易感性有关.
科学领域:
- 遗传学 遗传学 是一个
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
背景情况:
- 1型糖尿病 (T1D) 涉及胰腺β细胞的自身免疫破坏,受遗传和环境因素的影响.
- 维生素D受体 (VDR) 基因在胰岛素分泌和免疫反应调节中发挥作用.
- 在不同的人群中,VDR基因,维生素D和T1D之间的相互作用有所不同.
研究的目的:
- 调查南印度队列中VDR基因多态和T1D风险之间的关联.
- 分析T1D患者和对照组的维生素D水平.
主要方法:
- 一项涉及150名T1D患者和155名对照者的病例控制研究.
- 测量血清维生素D水平.
- 使用TaqMan实时测试进行VDR基因多态 (FokI,BsmI,TaqI) 的基因定型.
主要成果:
- 与对照组相比,T1D患者的维生素D水平显著降低.
- 在BSMI (rs1544410) VDR多态和T1D之间发现了显著的关联.
- 同卵性AA型BsmI基因型在T1D患者 (44%) 中比对照组 (23.2%) 更频繁,OR为2.265 (p < 0.001).
- 在T1D组中,BSMI的A等位基因也显着更为普遍 (p < 0.002).
- 特定的单元类型 (T-A-T和C-A-T) 统计学上与T1D易感性有关 (分别p < 0.008和p < 0.005).
- 对于FokI或TaqI多态,没有发现显著差异.
结论:
- 在VDR基因中的BSMI多态性和某些类型可能会导致南印度人群T1D易感性.
- 在这个队列中,较低的维生素D水平与T1D有关.
- 需要进一步的研究来阐明VDR基因变异在T1D病变发生过程中的作用.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
Diabetes Mellitus: Overview and Type I Subtype
5.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K
Principles of Pharmacogenetics: Types of Genetic Variants
60
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
60
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
65
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
80
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
80


